DEFEND-1

Showing 1 posts of 1 posts found.

Diabetes trial disappointment for GSK and Tolerx

March 14, 2011
Research and Development DEFEND-1, DEFEND-2, GSK, GlaxoSmithKline, Tolerx, diabetes, otelixizumab, type I diabetes

GSK and Tolerx’s type I diabetes drug otelixizumab has failed to meet its primary endpoint in a late-stage trial. Anti-CD3 …

The Gateway to Local Adoption Series

Latest content